M&T Bank Corp Raises Stake in Insmed, Inc. $INSM

M&T Bank Corp raised its position in shares of Insmed, Inc. (NASDAQ:INSM) by 123.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 9,150 shares of the biopharmaceutical company’s stock after purchasing an additional 5,056 shares during the period. M&T Bank Corp’s holdings in Insmed were worth $1,593,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in INSM. EULAV Asset Management purchased a new position in Insmed in the third quarter valued at approximately $12,961,000. Artisan Partners Limited Partnership increased its stake in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the last quarter. Atika Capital Management LLC purchased a new position in Insmed in the third quarter valued at approximately $13,681,000. Nisa Investment Advisors LLC increased its stake in Insmed by 374.6% in the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock valued at $1,507,000 after purchasing an additional 8,261 shares during the last quarter. Finally, Nordea Investment Management AB purchased a new position in Insmed in the fourth quarter valued at approximately $3,492,000.

Insmed Stock Performance

NASDAQ:INSM opened at $101.17 on Friday. The firm’s fifty day moving average price is $145.87 and its 200 day moving average price is $165.46. Insmed, Inc. has a 1-year low of $64.85 and a 1-year high of $212.75. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The firm has a market cap of $21.84 billion, a price-to-earnings ratio of -17.60 and a beta of 0.89.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 121.03% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter last year, the company earned ($1.42) earnings per share. Insmed’s quarterly revenue was up 229.7% compared to the same quarter last year. On average, sell-side analysts expect that Insmed, Inc. will post -2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus raised their target price on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Guggenheim lowered their target price on shares of Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research report on Friday. Roth Mkm restated a “buy” rating and set a $212.00 target price on shares of Insmed in a research report on Friday, April 17th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Finally, Barclays raised their target price on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Insmed presently has an average rating of “Buy” and a consensus target price of $211.86.

More Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares of the company’s stock, valued at $7,831,483.58. The trade was a 27.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 174,589 shares of company stock valued at $27,441,807 in the last 90 days. 2.10% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.